- Conditions
- Lyme Disease
- Interventions
- Placebo, TP-05 (lotilaner) High Dose, TP-05 (lotilaner) Low Dose
- Drug
- Lead sponsor
- Tarsus Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 700 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 19
- States / cities
- Pikesville, Maryland • Brookline, Massachusetts • Fall River, Massachusetts + 16 more
Location Directory
Clinical trials in New York, New York
This page shows live ClinicalTrials.gov search results for New York, New York, with direct links to official study records plus on-page filtering and sorting for broad location searches.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
10669
Shown on this page
12
Local exact-city summaries
10669
Based on exact city/state matches in the local index.
Local exact-city recruiting
2182
Live official results below use the broader ClinicalTrials.gov location search.
Showing 1–12 of 10,669 matching trials in New York, NY.
Indexed local directory records.
Top conditions in local exact-city summaries
Top sponsors in local exact-city summaries
Top therapies in local exact-city summaries
Indexed official records
Open in full search- Conditions
- Acute Stroke, Ischemic Stroke
- Interventions
- Zoom System
- Device
- Lead sponsor
- Imperative Care, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 750 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 10
- States / cities
- Huntsville, Alabama • Walnut Creek, California • Tampa, Florida + 7 more
- Conditions
- Post Traumatic Stress Disorder
- Interventions
- Placebo, TSND-201
- Drug
- Lead sponsor
- Transcend Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 26
- States / cities
- Little Rock, Arkansas • La Jolla, California • Los Angeles, California + 23 more
- Conditions
- Non Small Cell Lung Cancer (Squamous or Non Squamous), Stage 4 NSCLC
- Interventions
- EIK1001, Nab-paclitaxel + Carboplatin, Paclitaxel + Carboplatin, Pembrolizumab (KEYTRUDA®), Pemetrexed + Cisplatin /Carboplatin, Placebo
- Drug
- Lead sponsor
- Eikon Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 750 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2040
- U.S. locations
- 3
- States / cities
- Mineola, New York • New York, New York • White Plains, New York
- Conditions
- Brain Cancer, Central Nervous System Diseases, GBM, Glioblastoma (GBM), Glioblastoma Multiforme (GBM), Glioma, Newly Diagnosed Glioblastoma
- Interventions
- silevertinib in combination with temozolomide, temozolomide (TMZ)
- Drug
- Lead sponsor
- Black Diamond Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 162 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 7
- States / cities
- Springdale, Arkansas • Los Angeles, California • New Haven, Connecticut + 4 more
- Conditions
- Distal Esophageal Spasm, EGJ Outflow Obstruction With Spastic/Hypercontractile Features, Jackhammer Esophagus, Type III Achalasia
- Interventions
- Not listed
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 13
- States / cities
- Scottsdale, Arizona • La Jolla, California • Denver, Colorado + 10 more
- Conditions
- EGJ Outflow Obstruction Without Spastic/Hypercontractile Features, Type I Achalasia, Type II Achalasia
- Interventions
- Standard Myotomy, Tailored Short Myotomy
- Procedure
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 372 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 13
- States / cities
- Scottsdale, Arizona • La Jolla, California • Denver, Colorado + 10 more
- Conditions
- Advanced Endometrial Carcinoma, Recurrent Endometrial Carcinoma
- Interventions
- Bevacizumab, Biospecimen Collection, Carboplatin, Computed Tomography, Magnetic Resonance Imaging, Paclitaxel, Pembrolizumab
- Biological · Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 255 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 187
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Fayetteville, Arkansas + 149 more
- Conditions
- Amyotrophic Lateral Sclerosis (ALS)
- Interventions
- COYA 302, Placebo
- Drug
- Lead sponsor
- Coya Therapeutics
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 21
- States / cities
- Phoenix, Arizona • Los Angeles, California • San Francisco, California + 17 more
- Conditions
- Relapsed/Refractory Primary Central Nervous System Lymphoma
- Interventions
- Rituximab, Temozolomide, Tirabrutinib
- Drug
- Lead sponsor
- Ono Pharmaceutical Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 10
- States / cities
- Scottsdale, Arizona • Fullerton, California • New Haven, Connecticut + 5 more
- Conditions
- Locally Advanced Cervical Adenocarcinoma
- Interventions
- Biospecimen Collection, Brachytherapy, Carboplatin, Chest Radiography, Cisplatin, Computed Tomography, External Beam Radiation Therapy, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Paclitaxel, Pembrolizumab, Positron Emission Tomography
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 336 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 243
- States / cities
- Birmingham, Alabama • Fayetteville, Arkansas • Little Rock, Arkansas + 193 more
- Conditions
- FGFR Gene Alterations, FGFR Gene Amplification, FGFR3 Gene Alteration, FGFR3 Gene Fusions, FGFR3 Gene Mutation, Low-grade NMIBC
- Interventions
- TYRA-300 50mg, TYRA-300 60mg, TYRA-300 Dose TBD
- Drug
- Lead sponsor
- Tyra Biosciences, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 28
- States / cities
- Homewood, Alabama • Little Rock, Arkansas • Murrieta, California + 25 more